A board to discuss the Multiple Sclerosis modifying drug Copaxone

Postby Arron » Fri Jun 25, 2004 1:17 am

you're welcome, and the english medical term is "lipoatrophy"
User avatar
Volunteer Moderator
Posts: 893
Joined: Sun Feb 01, 2004 4:00 pm
Location: California, USA


Postby seahorse » Fri Jun 25, 2004 1:36 am

Arron, I will keep that in mind.
I already now about the english term for cruciate ligament, because I broke it last year in my right knee, and it was long-term therapie, so its really in my vocabulary now :wink: :wink: :wink:

So this board is not only good to get the latest news on MS, diskuss stuff, but also to broaden my vocabulary for free!!! What a great opportunity :lol: :lol: :lol:

Nice day, Antje.
"Anything essential is invisible to the eye.” Antoine de Saint Exupery, The Little Prince
User avatar
Getting to Know You...
Posts: 16
Joined: Sun Jun 20, 2004 3:00 pm
Location: leipzig, germany

Postby art » Fri Jun 25, 2004 4:51 am

I wrote to one of the Scientific Directors at Teva to ask about every other day Copaxone and this is what he said:

Koby Mok wrote:I know that some MS patients are using GA QOD dosing and are having
success with it. The bottom line is that Im glad to hear these patients are
doing well.

Copaxone QOD 20 mg dosing is not approved by the FDA, and should be
considered off-label use. I know that Teva is working on different
formulations to reduce the dosing interval. As to why the QD regimen was
chosen in the first place, the initial early animal and clinical trial data
indicated that the 20mg once a day dose was effective so this was utilized
in subsequent larger Phase III trials (these are now known as the "Pivotal
trials" as they were used by the FDA to establish GA's indication in RRMS).

I am aware of 2 publications (referenced below) that provide some insight
into Copaxone QOD dosing. This data is from an open-label, uncontrolled,
moderate-sized group of patients so should be interpreted given these
parameters. The other publication is in abstract form only. Please note:

Fletcher S, Kott E, Steiner-Birmanns B, et al. Copolymer 1 (glatiramer
acetate) in relapsing
forms of multiple sclerosis: open multicenter study of alternate-day
administration. Clin
Neuropharmacol. 2002;25(1):11-15.

Flechter S, Vardi J, Rabey JM: Comparison of efficacy between glatiramer
acetate and
Interferon b-1b in multiple sclerosis patients (MSpts): A two-year
follow-up study. Neurology
1999 Apr;52(Suppl 2):A497. (Abstract)

Again, Im happy to hear these patients are doing well. I believe this
gives impetus for more robust studies to confirm the small trial and
anecdotal findings thus far.
User avatar
Family Elder
Posts: 102
Joined: Tue May 18, 2004 3:00 pm
Location: Waltham, MA

Postby Arron » Fri Jun 25, 2004 8:24 am

Thank you for sharing that with us, Art! It's a good way of approaching this, and it's pretty refreshing to see a gigantic drug company being open-minded (of course, in this case, it IS in their favor as the more convenient Copax is, the more people will use it).
User avatar
Volunteer Moderator
Posts: 893
Joined: Sun Feb 01, 2004 4:00 pm
Location: California, USA


Postby Dawnsmspage » Sun Aug 22, 2004 9:43 pm

I just came across this and I am printing it out...thank you so much for the info!!
Dawn :)


Return to Copaxone


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service